PLT Health Solutions announced significant clinical trial results for its botanical sleep ingredient Serezin™ Restorative Sleep + Pain Relief, demonstrating substantial improvements in sleep quality and pain reduction. The company will present these findings at the American Academy of Sleep Medicine Conference in Seattle, Washington, from June 7-11, 2025.
Clinical Trial Demonstrates Multi-Faceted Benefits
A comprehensive 4-week, double-blind, placebo-controlled study involving 60 healthy men and women aged 50-70 years revealed substantial benefits across multiple sleep and pain parameters. Participants, who self-reported disturbed sleep due to everyday aches and pains, received either 300mg of Serezin daily or placebo, with measurements conducted at 1, 2, and 4-week intervals.
The study's primary findings showed that subjects taking Serezin experienced a 64% greater improvement in restorative sleep compared to placebo by the four-week mark. Notably, participants began waking up feeling more rested and restored within the first week of treatment.
Significant Pain Reduction Observed
Pain relief emerged as a key benefit, with significant improvements in pain scores beginning on Day 7 for the Serezin group. By Day 28, subjects taking Serezin experienced a 2.6x greater reduction in nighttime discomfort and a 75% greater reduction in daytime discomfort compared to the placebo group.
Sleep quality improvements were equally impressive, with statistically significant benefits appearing by Day 14. Subjects taking Serezin experienced improvements in falling asleep that were 85% greater than placebo and 93% greater improvements in sleep quality, as assessed by the Leeds Sleep Evaluation Questionnaire.
Mood and Wake-Up Experience Enhanced
The study also evaluated mood states using a validated questionnaire covering six domains: tension, depression, anger, vigor, fatigue, and confusion. Serezin subjects reported improved overall mood starting at Day 14, with a 2.2x improvement in overall mood compared to placebo.
Additionally, participants taking Serezin reported having a significantly easier time waking up in the morning and feeling more alert with better motor control upon waking, as assessed by the Leeds Sleep Evaluation Questionnaire.
Botanical Formulation and Research Presentation
Serezin combines two botanicals traditionally used in Ayurvedic medicine: Boswellia serrata (Indian Frankincense) and Zingiber Officinale (Ginger). The ingredient represents what PLT describes as "a different approach to promoting restorative sleep than many of the ingredients on the market today."
Dr. Dawna Salter-Farfan, PLT's Senior Clinical Research Manager and study author, will conduct a poster session on June 11, 2025, at 10:00 AM during the Clinical Sleep Science and Practice section. The presentation will focus specifically on results from the female-only cohort analysis.
"We are excited to present our high-impact research findings at SLEEP 2025," Dr. Salter-Farfan stated. "We will be showing data demonstrating Serezin improves sleep quality and quantity, but with a special emphasis on the improvements shown within the female-only cohort of our study."
Market Positioning and Future Applications
Steve Fink, Vice President of Marketing for PLT, emphasized the company's expanding portfolio in cognitive health solutions. "Cognitive health is an intense area of interest and innovation at PLT today, with a broad portfolio that addresses Cognitive Performance, Mental Energy, Stress and Mood and Sleep and Relaxation," he said.
The research findings have been published in an abstract titled "An Herbal Supplement Improves Restorative Sleep and Sleep Quality, Elevates Mood, and Increases Total Sleep Time" in the May edition of the journal SLEEP.
SLEEP 2025 represents the annual meeting of the Associated Professional Sleep Societies, LLC (APSS), a joint venture of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), and is considered the world's premier clinical and scientific meeting for sleep medicine and research.
